Comprehensive clinical, molecular and histopathological analysis of bone marrow in chronic myeloproliferative neoplasia

L Medina Vega; L Hernández Nieto; E Salido Ruíz; H Álvarez-Argüelles Cabrera; J M Raya Sánchez

doi:10.1016/j.rce.2018.11.012

Comprehensive clinical, molecular and histopathological analysis of bone marrow in chronic myeloproliferative neoplasia

Rev Clin Esp (Barc). 2019 Nov;219(8):440-444. doi: 10.1016/j.rce.2018.11.012. Epub 2019 Apr 7.

[Article in English, Spanish]

Authors

L Medina Vega¹, L Hernández Nieto², E Salido Ruíz³, H Álvarez-Argüelles Cabrera³, J M Raya Sánchez²

Affiliations

¹ Servicio de Bioquímica Clínica, Hospital Universitario de Canarias, La Laguna, Santa Cruz de Tenerife, España. Electronic address: lilianmedinatfe@hotmail.com.
² Servicio de Hematología y Hemoterapia, Hospital Universitario de Canarias, La Laguna, Santa Cruz de Tenerife, España.
³ Servicio de Anatomía Patológica, Hospital Universitario de Canarias, La Laguna, Santa Cruz de Tenerife, España.

PMID: 30971335
DOI: 10.1016/j.rce.2018.11.012

Abstract

Objectives: To analyse the possible correlation between molecular changes in the JAK2, MPL and CALR genes, the morphological pattern of bone marrow and the clinical-haematologic profile of patients.

Patients and methods: We conducted a retrospective study that included 140 patients diagnosed with Philadelphia-negative myeloproliferative neoplasia (Ph-MPN) in a single centre.

Results: In essential thrombocythaemia (ET), the patients with the JAK2 V617F mutation presented more leucocytes and neutrophils than patients who presented the CALR mutation, who had more platelets and a greater need for cytoreductive therapy. These findings support the fact that the mutational state in ET appears to define subtypes of patients with substantially different clinical courses and prognoses. In myelofibrosis, the mutational state appears to influence the histopathological changes found in the bone marrow biopsy, which did not occur in polycythaemia vera or ET.

Keywords: Biopsia de médula ósea; Bone marrow biopsy; CALR; Essential thrombocythaemia; JAK2; Mielofibrosis primaria; Myelofibrosis; Myeloproliferative neoplasia; Neoplasias mieloproliferativas; Policitemia vera; Polycythaemia vera; Trombocitemia esencial.